Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.

Rivera S, Leteur C, Mégnin F, Law F, Martins I, Kloos I, Depil S, Modjtahedi N, Perfettini JL, Hennequin C, Deutsch E.

Oncotarget. 2017 Jan 25;8(34):56210-56227. doi: 10.18632/oncotarget.14813. eCollection 2017 Aug 22.

2.

Pattern recognition receptors: immune targets to enhance cancer immunotherapy.

Shekarian T, Valsesia-Wittmann S, Brody J, Michallet MC, Depil S, Caux C, Marabelle A.

Ann Oncol. 2017 Aug 1;28(8):1756-1766. doi: 10.1093/annonc/mdx179. Review.

PMID:
28444111
3.

Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers.

Grandin M, Meier M, Delcros JG, Nikodemus D, Reuten R, Patel TR, Goldschneider D, Orriss G, Krahn N, Boussouar A, Abes R, Dean Y, Neves D, Bernet A, Depil S, Schneiders F, Poole K, Dante R, Koch M, Mehlen P, Stetefeld J.

Cancer Cell. 2016 Feb 8;29(2):173-85. doi: 10.1016/j.ccell.2016.01.001.

4.

Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma.

Markozashvili D, Pichugin A, Barat A, Camara-Clayette V, Vasilyeva NV, Lelièvre H, Kraus-Berthier L, Depil S, Ribrag V, Vassetzky Y.

Gene. 2016 Apr 15;580(2):134-43. doi: 10.1016/j.gene.2016.01.017. Epub 2016 Jan 13.

PMID:
26774800
5.

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer.

Legrier ME, Bièche I, Gaston J, Beurdeley A, Yvonnet V, Déas O, Thuleau A, Château-Joubert S, Servely JL, Vacher S, Lassalle M, Depil S, Tucker GC, Fontaine JJ, Poupon MF, Roman-Roman S, Judde JG, Decaudin D, Cairo S, Marangoni E.

Br J Cancer. 2016 Jan 19;114(2):177-87. doi: 10.1038/bjc.2015.398. Epub 2015 Dec 22.

6.

TIPIN depletion leads to apoptosis in breast cancer cells.

Baldeyron C, Brisson A, Tesson B, Némati F, Koundrioukoff S, Saliba E, De Koning L, Martel E, Ye M, Rigaill G, Meseure D, Nicolas A, Gentien D, Decaudin D, Debatisse M, Depil S, Cruzalegui F, Pierré A, Roman-Roman S, Tucker GC, Dubois T.

Mol Oncol. 2015 Oct;9(8):1580-98. doi: 10.1016/j.molonc.2015.04.010. Epub 2015 May 9.

7.

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.

Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R.

Oncotarget. 2015 Jun 10;6(16):14139-52.

8.

Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.

Morschhauser F, Terriou L, Coiffier B, Bachy E, Varga A, Kloos I, Lelièvre H, Sarry AL, Depil S, Ribrag V.

Invest New Drugs. 2015 Apr;33(2):423-31. doi: 10.1007/s10637-015-0206-x. Epub 2015 Jan 21.

PMID:
25600050
9.

HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.

de Cremoux P, Dalvai M, N'Doye O, Moutahir F, Rolland G, Chouchane-Mlik O, Assayag F, Lehmann-Che J, Kraus-Berthie L, Nicolas A, Lockhart BP, Marangoni E, de Thé H, Depil S, Bystricky K, Decaudin D.

Breast Cancer Res Treat. 2015 Jan;149(1):81-9. doi: 10.1007/s10549-014-3233-y. Epub 2014 Dec 12.

PMID:
25503779
10.

Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.

Loriot Y, Mordant P, Dugue D, Geneste O, Gombos A, Opolon P, Guegan J, Perfettini JL, Pierre A, Berthier LK, Kroemer G, Soria JC, Depil S, Deutsch E.

Cell Death Dis. 2014 Sep 18;5:e1423. doi: 10.1038/cddis.2014.365.

11.

Epstein-Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients.

Morales O, Mrizak D, François V, Mustapha R, Miroux C, Depil S, Decouvelaere AV, Lionne-Huyghe P, Auriault C, de Launoit Y, Pancré V, Delhem N.

Br J Haematol. 2014 Sep;166(6):875-90. doi: 10.1111/bjh.12980. Epub 2014 Jul 9.

PMID:
25041527
12.

Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts.

Gressette M, Vérillaud B, Jimenez-Pailhès AS, Lelièvre H, Lo KW, Ferrand FR, Gattolliat CH, Jacquet-Bescond A, Kraus-Berthier L, Depil S, Busson P.

PLoS One. 2014 Mar 11;9(3):e91325. doi: 10.1371/journal.pone.0091325. eCollection 2014.

13.

Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.

Némati F, de Montrion C, Lang G, Kraus-Berthier L, Carita G, Sastre-Garau X, Berniard A, Vallerand D, Geneste O, de Plater L, Pierré A, Lockhart B, Desjardins L, Piperno-Neumann S, Depil S, Decaudin D.

PLoS One. 2014 Jan 13;9(1):e80836. doi: 10.1371/journal.pone.0080836. eCollection 2014.

14.

The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.

Salvador MA, Wicinski J, Cabaud O, Toiron Y, Finetti P, Josselin E, Lelièvre H, Kraus-Berthier L, Depil S, Bertucci F, Collette Y, Birnbaum D, Charafe-Jauffret E, Ginestier C.

Clin Cancer Res. 2013 Dec 1;19(23):6520-31. doi: 10.1158/1078-0432.CCR-13-0877. Epub 2013 Oct 18.

15.

Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms.

Ali A, Bluteau O, Messaoudi K, Palazzo A, Boukour S, Lordier L, Lecluse Y, Rameau P, Kraus-Berthier L, Jacquet-Bescond A, Lelièvre H, Depil S, Dessen P, Solary E, Raslova H, Vainchenker W, Plo I, Debili N.

Cell Death Dis. 2013 Jul 25;4:e738. doi: 10.1038/cddis.2013.260.

16.

S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.

Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Léonce S, Ferry G, Da Violante G, Bouzom F, Cattan V, Jacquet-Bescond A, Comoglio PM, Lockhart BP, Boutin JA, Cordi A, Ortuno JC, Pierré A, Hickman JA, Cruzalegui FH, Depil S.

Mol Cancer Ther. 2013 Sep;12(9):1749-62. doi: 10.1158/1535-7163.MCT-13-0075. Epub 2013 Jun 26.

17.

Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.

Fouliard S, Robert R, Jacquet-Bescond A, du Rieu QC, Balasubramanian S, Loury D, Loriot Y, Hollebecque A, Kloos I, Soria JC, Chenel M, Depil S.

Eur J Cancer. 2013 Sep;49(13):2791-7. doi: 10.1016/j.ejca.2013.05.009. Epub 2013 Jun 18.

PMID:
23790467
18.

Decoding and unlocking the BCL-2 dependency of cancer cells.

Juin P, Geneste O, Gautier F, Depil S, Campone M.

Nat Rev Cancer. 2013 Jul;13(7):455-65. doi: 10.1038/nrc3538. Epub 2013 Jun 20. Review.

PMID:
23783119
19.

Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.

Chalret du Rieu Q, Fouliard S, Jacquet-Bescond A, Robert R, Kloos I, Depil S, Chatelut E, Chenel M.

Pharm Res. 2013 Oct;30(10):2640-53. doi: 10.1007/s11095-013-1089-1. Epub 2013 Jun 5.

PMID:
23737346
20.

TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.

Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A, Gentien D, Barillot E, Roman-Roman S, Depil S, Cruzalegui F, Pierré A, Tucker GC, Dubois T.

PLoS One. 2013 May 20;8(5):e63712. doi: 10.1371/journal.pone.0063712. Print 2013.

21.

Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.

Maire V, Némati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost B, De Koning L, Lang G, Gentien D, Dumont A, Barillot E, Marangoni E, Decaudin D, Roman-Roman S, Pierré A, Cruzalegui F, Depil S, Tucker GC, Dubois T.

Cancer Res. 2013 Jan 15;73(2):813-23. doi: 10.1158/0008-5472.CAN-12-2633. Epub 2012 Nov 9.

22.

Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept.

Wurch T, Pierré A, Depil S.

Trends Biotechnol. 2012 Nov;30(11):575-82. doi: 10.1016/j.tibtech.2012.07.006. Epub 2012 Sep 1. Review.

PMID:
22944617
23.

EBV Latency II-derived peptides induce a specific CD4+ cytotoxic T-cell activity and not a CD4+ regulatory T-cell response.

Moralès O, Depil S, Mrizak D, Martin N, Ndour PA, Dufosse F, Miroux C, Coll J, de Launoit Y, Auriault C, Pancre V, Delhem N.

J Immunother. 2012 Apr;35(3):254-66. doi: 10.1097/CJI.0b013e31824d72c5.

PMID:
22421943
24.

Presence of HIV-1 Nef specific CD4 T cell response is associated with non-progression in HIV-1 infection.

Pancré V, Delhem N, Yazdanpanah Y, Delanoye A, Delacre M, Depil S, Moralès O, Mouton Y, Auriault C.

Vaccine. 2007 Aug 1;25(31):5927-37. Epub 2007 Jun 11.

PMID:
17600593
25.

Comparative analysis of naïve and memory CD4+ and CD8+ T-cell subsets in bone marrow and G-CSF-mobilized peripheral blood stem cell allografts: impact of donor characteristics.

Yakoub-Agha I, Saule P, Depil S, Grutzmacher C, Boulanger F, Magro L, Jouet JP, Dessaint JP, Labalette M.

Exp Hematol. 2007 Jun;35(6):861-71.

PMID:
17533040
26.

Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies.

Depil S, Moralès O, Castelli FA, Delhem N, François V, Georges B, Dufossé F, Morschhauser F, Hammer J, Maillère B, Auriault C, Pancré V.

J Immunother. 2007 Feb-Mar;30(2):215-26.

PMID:
17471168
27.

Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma.

Morschhauser F, Depil S, Jourdan E, Wetterwald M, Bouabdallah R, Marit G, Solal-Céligny P, Sebban C, Coiffier B, Chouaki N, Bauters F, Dumontet C.

Ann Oncol. 2007 Feb;18(2):370-5. Epub 2006 Oct 30.

PMID:
17074972
28.

A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy.

Yakoub-Agha I, Saule P, Depil S, Micol JB, Grutzmacher C, Boulanger-Villard F, Bauters F, Jouet JP, Dessaint JP, Labalette M.

Leukemia. 2006 Sep;20(9):1557-65. Epub 2006 Jul 6.

PMID:
16826221
29.

Peptide-binding assays and HLA II transgenic Abeta degrees mice are consistent and complementary tools for identifying HLA II-restricted peptides.

Depil S, Angyalosi G, Moralès O, Delacre M, Delhem N, François V, Georges B, Hammer J, Maillère B, Auriault C, Pancré V.

Vaccine. 2006 Mar 20;24(13):2225-9. Epub 2005 Dec 9.

PMID:
16469420
30.

Outcome of patients less than 55 years of age with high-risk acute leukemia who did not have an human leukocyte antigen-identical related donor: a long-term study of 97 consecutive patients.

Cornillon J, Fawaz A, Depil S, Dufosse F, Duhamel A, Bauters F, Fenaux P, Jouet JP, Yakoub-Agha I.

Leuk Lymphoma. 2005 Jun;46(6):841-9.

PMID:
16019528
31.

Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma.

Depil S, Mathiot C, Leleu X, Moreau AS, Faucompré JL, Hennache B, Bauters F, Bataille R, Facon T.

Br J Haematol. 2005 Jun;129(5):706-7. No abstract available.

PMID:
15916694
32.

Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival.

Leleu X, Genevieve F, Guieze R, Duhamel A, Andrieux J, Berthon C, Godon A, Prat-Lesaffre S, Depil S, Lai JL, Facon T, Zandecki M; Intergroupe Francophone du Myelome (IFM).

Leuk Res. 2005 Jun;29(6):665-71. Epub 2005 Mar 28.

PMID:
15863207
33.

Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myeloma.

Depil S, Leleu X, Micol JB, Berthon C, Laï JL, Bauters F, Quesnel B, Facon T.

Leuk Lymphoma. 2004 Dec;45(12):2481-4.

PMID:
15621764
34.

Impact of Small Bowel Exploration Using Video-Capsule Endoscopy in the Management of Acute Gastrointestinal Graft-versus-Host Disease.

Yakoub-Agha I, Maunoury V, Wacrenier A, Couignoux S, Depil S, Desreumaux P, Bauters F, Colombel JF, Jouet JP.

Transplantation. 2004 Dec 15;78(11):1697-701.

PMID:
15591963
35.

[Hodgkin's disease and Epstein-Barr virus].

Depil S, Moralès O, Auriault C.

Ann Biol Clin (Paris). 2004 Nov-Dec;62(6):639-48. Review. French.

36.

Efficient generation of antileukemic autologous T cells by short-term culture and gamma-irradiation of myeloid leukemic cells.

Vereecque R, Saudemont A, Depil S, Corm S, Andrieux J, Soenen-Cornu V, Quesnel B.

Cancer Immunol Immunother. 2004 Sep;53(9):793-8. Epub 2004 Apr 20.

PMID:
15098140
37.

A case of refractory anemia with 17p- syndrome following azathioprine treatment for heart transplantation.

Depil S, Lepelley P, Soenen V, Preudhomme C, Lai JL, Broly F, Quesnel B.

Leukemia. 2004 Apr;18(4):878. No abstract available.

PMID:
14961032
38.

Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome.

Depil S, Deconinck E, Milpied N, Sutton L, Witz F, Jouet JP, Damaj G, Yakoub-Agha I; Société Française de Greffe de Moelle et Thérapie cellulaire.

Bone Marrow Transplant. 2004 Mar;33(5):531-4.

PMID:
14716345
39.

Chemotherapy increases transgene expression in leukemic cells.

Vereecque R, Saudemont A, Depil S, Quesnel B.

J Gene Med. 2003 Oct;5(10):852-859. doi: 10.1002/jgm.413.

PMID:
14533193
40.

SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma.

Depil S, Saudemont A, Quesnel B.

Leukemia. 2003 Aug;17(8):1678-9. No abstract available.

PMID:
12886263
41.

Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma.

Guillerm G, Depil S, Wolowiec D, Quesnel B.

Haematologica. 2003 Apr;88(4):476-8. No abstract available.

42.

Primary central nervous system lymphoma in immunocompetent adults: poor results mainly associated with high treatment related toxicities.

Depil S, Coiteux V, Guillerm G, Gyan E, Bauters F, Fenaux P, Quesnel B.

Leuk Lymphoma. 2002 Sep;43(9):1819-22.

PMID:
12685838
43.

Expression of a human endogenous retrovirus, HERV-K, in the blood cells of leukemia patients.

Depil S, Roche C, Dussart P, Prin L.

Leukemia. 2002 Feb;16(2):254-9.

Supplemental Content

Support Center